Us Bancorp \De\ Catalyst Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

$74.1 Billion
Q1 2025

A detailed history of Us Bancorp \De\ transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 7,328 shares of CPRX stock, worth $179,829. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,328

Previous 6,223 17.76%

Holding current value

$179,829

Previous $129,000 37.21%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$19.53 - $25.74 $21,580 - $28,442	1,105 Added 17.76%	7,328 $177,000
Q4 2024 Feb 05, 2025	SELL	$19.73 - $23.93 $772,429 - $936,859	-39,150 Reduced 86.28%	6,223 $129,000
Q3 2024 Oct 28, 2024	SELL	$15.19 - $21.35 $59,013 - $82,944	-3,885 Reduced 7.89%	45,373 $902,000
Q2 2024 Aug 06, 2024	BUY	$14.68 - $16.92 $11,347 - $13,079	773 Added 1.59%	49,258 $763,000
Q1 2024 May 07, 2024	SELL	$13.18 - $17.11 $219,974 - $285,565	-16,690 Reduced 25.61%	48,485 $772,000
Q4 2023 Feb 09, 2024	BUY	$11.78 - $17.29 $299,424 - $439,477	25,418 Added 63.93%	65,175 $1.1 Million
Q3 2023 Nov 03, 2023	SELL	$11.69 - $15.02 $69,672 - $89,519	-5,960 Reduced 13.04%	39,757 $464,000
Q2 2023 Aug 09, 2023	BUY	$11.5 - $18.08 $92,713 - $145,760	8,062 Added 21.41%	45,717 $614,000
Q1 2023 May 09, 2023	BUY	$14.34 - $21.05 $538,366 - $790,280	37,543 Added 33520.54%	37,655 $624,000
Q4 2022 Feb 13, 2023	BUY	$12.25 - $19.5 $147 - $234	12 Added 12.0%	112 $2,000
Q1 2022 May 11, 2022	BUY	$5.31 - $8.31 $531 - $831	100 New	100 $1,000

Others Institutions Holding CPRX

# of Institutions

388

Shares Held

99.3M

Call Options Held

37K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.52B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account